A Phase 1 interventional study of Oral [14C] PF-07248144 and Oral unlabeled PF-07248144 in Healthy Adult Participants, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
For this study, the study medicine has been specially prepared to contain radiolabeled carbon [14C]. [14C] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study medicine does not change how the medicine works but helps to see how the medicine appears in the blood, urine, and stool after it is given. This type of study is called a radiolabeled study.
The purpose of this radiolabeled study is to learn how a certain amount of [14C] PF-07248144 is taken up into the bloodstream and removed from the body.
The study is seeking participants who are:
The study consists of two parts. In part one, all participants will receive one full dose of [14C]PF-07248144 by mouth. Part two will begin at least 28 days after the dose in part one. In part two, participants will receive one full dose of PF-07248144 by mouth and one small dose of [14C] PF-07248144 by intravenous (IV) infusion. IV infusion will be directly injected into the veins.
To understand how the medicine is processed in the body, samples of blood, urine, feces, and vomit (if any) will be collected after each dose is given. This will help understand:
Participants will take part in the study for about 15 weeks, including evaluation at the start and follow-up period.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one dose of \[14C\] PF-07248144 by mouth in Period 1. After a washout, participants will receive one dose of PF-07248144 by mouth and one intravenous (IV) infusion of \[14C\] PF-07248144 in Period 2
Drug: Oral [14C] PF-07248144 · Drug: Oral unlabeled PF-07248144 · Drug: IV [14C] PF-07248144
A single oral dose of \[14C\] PF-07248144 will be administered as an extemporaneous suspension in Period 1
A single oral dose of unlabeled PF-07248144 will be administered as tablets in Period 2
A single IV infusion of \[14C\] PF-07248144 will be administered at the approximate Tmax after administration of the unlabeled oral dose of PF-07248144 in Period 2
Total recovery of radioactivity in urine, feces and vomitus (if any) expressed as a percent of total radioactive dose administered.
To characterize the extent of excretion of total radioactivity in urine, feces, and vomitus (if any) following administration of a single oral dose of \[14C\]PF-07248144.
Time frame: Period 1 pre-dose to maximum Days 22
Metabolic profiling/identification and determination of relative abundance of [14C]PF-07248144 and the metabolites of [14C]PF-07248144 in plasma, urine, and feces.
To characterize the metabolic profile and identify circulating and excreted metabolites following administration of a single oral dose of \[14C\]PF-07248144.
Time frame: Period 1 pre-dose to maximum Days 22
The ratio of dose-normalized plasma AUCinf (if data permit, otherwise AUClast) of oral unlabeled PF-07248144 and IV microtracer of [14C]PF-07248144 in Period 2 only.
To determine the absolute oral bioavailability (F) of PF-07248144 following administration of a single oral dose of PF-07248144 compared to a single IV microtracer of \[14C\]PF-07248144.
Time frame: Period 2 pre-dose to maximum Days 10
The ratio of total urinary radioactivity following oral administration of [14C]PF-07248144 in Period 1 and IV microtracer, microdose administration of [14C]PF-07248144 in Period 2.
To determine the fraction of the dose absorbed (Fa) following administration of a single oral dose of \[14C\]PF-07248144.
Time frame: Period 1 pre-dose to maximum Days 22; Period 2 pre-dose to maximum Days 10
Number of Participants With Treatment Emergent Adverse Events
Time frame: Baseline and through 28 to 35 days post last study intervention dose
Number of Participants with Treatment Emergent Clinically Significant Laboratory Abnormalities
Time frame: From Baseline up to 28 to 35 days post last study intervention dose
Number of Participants With Treatment Emergent Clinically Significant Abnormal Vital Signs
Time frame: From Baseline up to 28 to 35 days post last study intervention dose
Number of Participants With Treatment Emergent Clinically Significant Physical Examination Abnormalities
Time frame: From Baseline up to 28 to 35 days post last study intervention dose
Number of Participants With Treatment Emergent Clinically Significant Abnormal ECG Measurements
Time frame: From Baseline up to 28 to 35 days post last study intervention dose
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2025 to primary completion in Dec 2025, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prifetrastat